Phase 1/2a Clinical Trial of T3011, an Oncolytic HSV Delivering IL-12 and PD-1 Antibody, Administered Intratumorally as a Monotherapy for Advanced Solid Tumors, Including Recurrent or Metastatic HNSCC - Scorecard - DentalSpire
Advertisement
Phase 1/2a Clinical Trial of T3011, an Oncolytic HSV Delivering IL-12 and PD-1 Antibody, Administered Intratumorally as a Monotherapy for Advanced Solid Tumors, Including Recurrent or Metastatic HNSCC
Clinical Scorecard: Phase 1/2a Clinical Trial of T3011, an Oncolytic HSV Delivering IL-12 and PD-1 Antibody, Administered Intratumorally as a Monotherapy for Advanced Solid Tumors, Including Recurrent or Metastatic HNSCC
At a Glance
Category
Detail
Condition
Advanced or metastatic solid tumors including recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
Key Mechanisms
Oncolytic virus-mediated direct tumor cell lysis and localized expression of IL-12 and anti-PD-1 antibody to enhance systemic anti-tumor immunity
Target Population
Patients with advanced or metastatic solid tumors, specifically including recurrent or metastatic HNSCC
Care Setting
Multicenter clinical trial setting with intratumoral administration
Key Highlights
T3011 combines oncolytic HSV with IL-12 and anti-PD-1 antibody transgenes to induce potent local and systemic anti-tumor immune responses.
Intratumoral injection confines IL-12 bioactivity to the tumor microenvironment, reducing systemic toxicity associated with IL-12 therapy.
Phase 1/2a trial includes dose-escalation and expansion phases evaluating safety, efficacy, viral biodistribution, and shedding in advanced solid tumors.
Guideline-Based Recommendations
Diagnosis
Identify patients with advanced or metastatic solid tumors including recurrent or metastatic HNSCC.
Assess HPV status in HNSCC due to prognostic implications.
Management
Consider intratumoral administration of T3011 as monotherapy in clinical trial settings for patients with limited treatment options.
Use dose-escalation protocols to determine recommended phase 2 dose (RP2D).
Monitor for safety and efficacy during and after treatment.
Monitoring & Follow-up
Evaluate dose-limiting toxicities within 28 days post initial administration.
Conduct safety follow-up visits 30 days after last dose.
Perform survival follow-up every 3 months up to 2 years post-treatment.
Risks
Potential immune-related adverse events mitigated by localized expression of IL-12 and PD-1 antibody.
Systemic toxicity from IL-12 minimized by intratumoral delivery.
Monitor for viral shedding and biodistribution.
Patient & Prescribing Data
Patients with advanced or metastatic solid tumors, including recurrent or metastatic HNSCC, refractory to standard therapies.
Intratumoral T3011 administration achieves localized high concentrations of IL-12 and PD-1 antibody, enhancing anti-tumor immunity while reducing systemic toxicity compared to systemic cytokine or checkpoint inhibitor delivery.
Clinical Best Practices
Employ intratumoral injection to confine therapeutic cytokine and antibody expression to tumor microenvironment.
Use 3 + 3 dose-escalation design to establish safety and RP2D.
Incorporate HPV status assessment in HNSCC patients for prognostic stratification.
Follow patients longitudinally for safety, efficacy, and survival outcomes.
Consider intranodal injection as a potential alternative delivery route to enhance immune cell exposure.
This quality improvement project found that using a distress screening tool for head and neck cancer patients who were 2 or more years post-treatment led to an increased number of referrals for psychosocial needs.
